Agrospheres Completes Expansion of $25 Million Series B Round

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection, today announced the closing of its Series B funding round with a strategic investment from FMC Corporation (NYSE: FMC), a global leader in agriculture sciences. This investment brings the total funding in AgroSpheres’ Series B round to $25 million, demonstrating the strong confidence in the company’s innovative solutions. FMC Ventures joins Lewis and Clark AgriFood, Ospraie Ag Science, BIDRA Ventures, and Cavallo Ventures to close out the round.

AgroSpheres has developed cutting-edge technology that enables precise delivery of active ingredients such as small molecules, peptides, and nucleic acids in crop protection products. This technology has the potential to revolutionize the agriculture industry by improving the efficiency, efficacy, and sustainability of crop protection practices.

“We are excited to invest and partner with AgroSpheres, sharing a common vision for advancing agriculture,” said Mark Brooks, managing director, FMC Ventures. “Their innovative technology has the potential to be a game changer in crop protection. With broad IP protection, manufacturing capabilities, and a strong industry network, AgroSpheres stands out in AgTech. We believe this investment will drive innovation and accelerate the development of sustainable solutions for farmers globally.”

AgroSpheres’ Co-Founder and CEO, Payam Pourtaheri, also commented on the investment, saying, “We are honored to welcome FMC Corporation as a strategic investor in AgroSpheres. Their extensive expertise in agricultural sciences and global reach make them an ideal partner for us. This investment will further empower us to continue our mission of providing more effective and sustainable solutions for the agricultural industry. Together with FMC, we will strive to make a significant impact on global agriculture.”

AgroSpheres has gained recognition for its innovative approach to precision delivery of crop protection products, reducing environmental impact, and enhancing overall crop health. This latest investment will support the company in its mission to bring this technology to more markets, helping farmers worldwide address the challenges of feeding a growing global population while minimizing the environmental footprint.

Recent News


Protected: Don’t Miss These Spring Talent Events

There is no excerpt because this is a protected post.


SRI selected as spoke for both ARPA-H Customer Experience Hub and Investor Catalyst Hub

SRI has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to serve as a spoke within the Customer Experience Hub (CX Hub) and the Investor Catalyst Hub (IC Hub), as part of ARPANET-H, a nationwide health innovation network launched in September 2023. “Hundreds of organizations have been selected to join each network.


ReAlta Life Sciences Announces Dosing of First Patient in Phase 2 Trial of RLS-0071 for Acute Exacerbations of Chronic Obstructive Pulmonary Disease

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, announced enrollment of the first patient in a Phase 2 clinical trial evaluating the safety and efficacy of RLS-0071, an investigational new drug based on ReAlta’s novel EPICC peptide